London, 6 September 2016:
EVVIVAX has participated at the meeting "Comparative Oncology: The Next Frontier?", held at Royal Veterinary College, Royal College Street, London NW1 0TU.
Dr L. Aurisicchio (EVVIVAX CEO) presented "Novel immunotherapeutic approaches to canine lymphoma“
Engineered Veterinary Vectored Immunotherapy and Vaccines: EVVIVAX
EVVIVAX stems from new, European platform technologies, aims to offer novel therapeutic avenues to pet cancer patients, with the strong translational potential to complement current human Immune-Oncology approaches in the next future.
